For decades, cardiovascular risk assessment focused primarily on cholesterol levels, blood pressure, diabetes, and smoking status. While these remain critical predictors, research over the past 20 years has clarified that atherosclerosis is fundamentally an inflammatory disease of the arterial wall (Libby, 2002; Hansson, 2005).
Atherosclerotic plaques are not simply accumulations of fat. They are biologically active structures composed of lipids, inflammatory cells, cytokines, and connective tissue. Chronic low-grade vascular inflammation contributes to plaque progression and instability, increasing the risk of thrombosis and myocardial infarction. Understanding this inflammatory component has expanded how clinicians approach cardiovascular prevention.
C-reactive protein (CRP) is an acute-phase protein produced by the liver in response to systemic inflammation. Standard CRP testing detects acute inflammatory states such as infection. High-sensitivity CRP (hs-CRP) testing measures much lower concentrations and is used to assess chronic low-grade inflammation.
Multiple large-scale studies have demonstrated that elevated hs-CRP levels are associated with increased risk of cardiovascular events, independent of LDL cholesterol levels (Ridker et al., 1997; Ridker et al., 2002).
The American Heart Association (AHA) and Centers for Disease Control and Prevention (CDC) have previously provided guidance suggesting that:
(Pearson et al., 2003)
It is important to emphasize that hs-CRP is not diagnostic of heart disease. It is a risk-modifying marker that must be interpreted alongside lipid profile, blood pressure, glycaemic status, and overall clinical assessment.
Atherosclerosis begins with endothelial dysfunction. Oxidized LDL particles trigger inflammatory signaling, attracting immune cells into the arterial wall. These cells release cytokines and proteolytic enzymes that contribute to plaque development and eventual instability (Hansson, 2005).
Plaque rupture exposes thrombogenic material, triggering clot formation. If the clot obstructs coronary blood flow, myocardial infarction may occur.
The importance of inflammation in cardiovascular disease was further confirmed by the CANTOS trial, which demonstrated that targeting inflammation (independent of lipid lowering) reduced recurrent cardiovascular events (Ridker et al., 2017).
This landmark study reinforced the concept that inflammation is not merely associated with heart disease — it plays a causal role.
Traditional tools such as electrocardiography detect electrical abnormalities. Stress testing evaluates inducible ischemia. Troponin identifies active myocardial injury. Lipid panels assess cholesterol fractions.
hs-CRP, however, reflects systemic inflammatory burden. It does not detect blockage directly but may help refine risk stratification in patients without overt symptoms.
Current preventive cardiology emphasizes a multifactorial risk assessment model that may include inflammatory markers in selected individuals (Grundy et al., 2019).
Lifestyle modification remains foundational in cardiovascular prevention.
A Mediterranean-style diet rich in vegetables, fruits, legumes, whole grains, nuts, and olive oil has been associated with reduced inflammatory markers and lower cardiovascular risk (Estruch et al., 2013).
Regular physical activity improves endothelial function and reduces inflammatory cytokines. Weight reduction in overweight individuals lowers hs-CRP levels (Selvin et al., 2007).
Smoking cessation significantly reduces systemic inflammation. Adequate sleep and stress regulation also influence inflammatory pathways through neuroendocrine mechanisms.
Stress activates the hypothalamic–pituitary–adrenal axis, elevating cortisol and pro-inflammatory mediators, which may contribute to vascular dysfunction over time.
Traditional systems of medicine conceptualize inflammation differently, often through metabolic or constitutional imbalance frameworks. In integrative settings, dietary regulation, structured routines, and physician-supervised herbal formulations may be considered supportive.
However, no herbal or detoxification therapy should replace statins, antihypertensives, antiplatelet agents, or other evidence-based cardiac treatments when clinically indicated.
Cardiovascular disease requires coordinated care with qualified healthcare professionals.
Cardiovascular disease is driven by both lipid accumulation and chronic inflammation. High-sensitivity CRP offers additional insight into inflammatory risk and may help refine preventive strategies in selected patients.
Reducing systemic inflammation through evidence-based lifestyle modification remains a cornerstone of cardiovascular prevention. Integrative strategies may complement care but should always be aligned with established cardiology guidelines.
The objective of prevention is long-term vascular stability, reduced event risk, and sustained metabolic balance.
Estruch, R. et al. (2013). Primary prevention of cardiovascular disease with a Mediterranean diet. [LINK]
Grundy, S.M. et al. (2019). 2018 AHA/ACC guideline on the management of blood cholesterol. [LINK]
Hansson, G.K. (2005). Inflammation, atherosclerosis, and coronary artery disease. [LINK]
Libby, P. (2002). Inflammation in atherosclerosis. [LINK]
Pearson, T.A. et al. (2003). Markers of inflammation and cardiovascular disease: Application to clinical practice. [LINK]
Ridker, P.M. et al. (1997). Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. [LINK]
Ridker, P.M. et al. (2002). C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease. [LINK]
Ridker, P.M. et al. (2017). Antiinflammatory therapy with canakinumab for atherosclerotic disease. [LINK]
Selvin, E. et al. (2007). The impact of weight reduction on C-reactive protein. [LINK]
This article is intended for educational purposes only and does not constitute medical advice. Cardiovascular disease requires evaluation by qualified healthcare professionals. Laboratory markers such as hs-CRP should be interpreted within a comprehensive clinical context. Integrative therapies should not replace prescribed cardiac treatment.
